Retatrutide (LY3437943) is an investigational once-weekly injectable peptide that activates three receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It has been studied in adults with obesity or overweight, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), obstructive sleep apnoea and knee osteoarthritis, in trials sponsored by Eli Lilly. It is not an approved medicine in the sources checked.
Research overview
Retatrutide is a GIP/GLP-1/glucagon triple receptor agonist in development for obesity and related metabolic conditions. It has reached registrational Phase 3 testing through the TRIUMPH program, a set of four multicenter randomized trials enrolling over 5,800 participants. Peer-reviewed Phase 3 results have now been published for TRIUMPH-1 and TRIUMPH-2, and the registry lists TRIUMPH-1 to TRIUMPH-4 as completed, while further Phase 3 studies remain active. No approved indication was identified in the sources checked.
Mechanism of action
Retatrutide is described as a single peptide that acts as an agonist at the glucagon receptor, the GIP receptor and the GLP-1 receptor. In the original discovery and early clinical paper, in vitro testing showed balanced glucagon-receptor and GLP-1-receptor activity with comparatively more GIP-receptor activity [PMID 35985340].
In obese mice in that paper, body-weight loss was reported to be augmented when glucagon-receptor-mediated increases in energy expenditure were added to the reduced calorie intake driven by GIP- and GLP-1-receptor activity [PMID 35985340]. This is an experimental-model finding and does not by itself show the same balance of effects in people.
A recent narrative review describes retatrutide as a lipidated 39-residue peptide suited to once-weekly administration, and notes that its gastrointestinal effects, heart-rate changes and the functional consequences of lean-mass loss require further evaluation [PMID 42942810].
Adult human evidence
A randomised, double-blind, placebo-controlled Phase 2 trial in 338 adults with obesity or overweight (with at least one weight-related condition) reported dose-dependent reductions in body weight over 48 weeks compared with placebo. The most common adverse events were gastrointestinal, were dose-related and mostly mild to moderate, and dose-dependent increases in heart rate were observed that peaked at 24 weeks and declined thereafter [PMID 37366315].
In a Phase 2 trial in 281 adults aged 18-75 years with type 2 diabetes, retatrutide groups showed larger reductions in HbA1c and body weight than placebo at 24 and 36 weeks, and some groups showed larger reductions than the dulaglutide comparator. Mild-to-moderate gastrointestinal adverse events were more frequent in retatrutide groups, and no severe hypoglycaemia or deaths were reported [PMID 37385280]. A prespecified substudy of this trial (189 participants) measured total fat mass by DXA; it reported reductions in fat mass versus placebo and dulaglutide at higher dose groups, with a proportion of lean-mass loss that the authors described as similar to other obesity treatments [PMID 40609566].
A randomised Phase 2a substudy in 98 participants from the obesity trial who had MASLD with at least 10% liver fat reported large relative reductions in liver fat at 24 weeks compared with placebo, and that liver-fat reductions were significantly related to changes in body weight, abdominal fat and metabolic measures [PMID 38858523]. This was a liver-fat imaging endpoint; it does not show effects on liver histology or clinical outcomes.
Phase 3 results have since been published. In TRIUMPH-1, 2,339 adults with obesity without diabetes were randomised to retatrutide or placebo for 80 weeks; the reported mean body-weight change in the highest-dose group was -25.0% versus -3.9% with placebo (treatment-regimen estimand), the most common adverse events were gastrointestinal, and prespecified subgroups of participants with knee osteoarthritis or obstructive sleep apnoea showed reductions in pain score and apnoea-hypopnoea index respectively [PMID 42814954]. Companion NEJM reports describe the knee osteoarthritis trials (TRIUMPH-4 and TRIUMPH-1-OA, [PMID 43001755]) and the obstructive sleep apnoea trials (TRIUMPH-1-OSA and TRIUMPH-2-OSA, [PMID 42904878]); these reports state that serious adverse events were more common with retatrutide than placebo in the osteoarthritis trials.
In TRIUMPH-2, 1,152 adults with obesity and type 2 diabetes were randomised for 80 weeks; mean body-weight changes with retatrutide were larger than with placebo across the three tested groups. Gastrointestinal events, hypotension and dysaesthesia were reported more often with retatrutide, and permanent discontinuation due to adverse events or death was more frequent in the two higher-dose groups than with placebo [PMID 42810372]. In TRANSCEND-T2D-1, a 40-week trial in 537 adults with type 2 diabetes inadequately controlled by diet and exercise, HbA1c and body weight fell more with retatrutide than with placebo, with mostly mild-to-moderate gastrointestinal events [PMID 42250575].
Preclinical evidence
The discovery paper reported in vitro receptor activity and, in obese mice, decreased body weight and improved glycaemic control with retatrutide; it also reports a Phase 1 single-ascending-dose study in which safety and tolerability were described as similar to other incretins and a body-weight reduction persisted to day 43 after a single dose. The participant age is not stated in the abstract [PMID 35985340].
In diet-induced obese MASH mouse and hamster models, retatrutide was reported to reduce body weight (about 31% in mice), insulin-resistance index, plasma lipids and, in hamsters, hepatic triglyceride content, although histopathological scoring was not reduced in hamsters [PMID 41741376].
In diet-induced obese male rats, combined daily administration of retatrutide with cagrilintide was reported to reduce body weight and food intake more than the single agents, and more than matched combinations that included semaglutide or tirzepatide. This is an animal study of a combination not tested here in humans [PMID 42744908].
Evidence limitations
Retatrutide is investigational; no approved indication was identified in the sources checked, and approval or labelling does not apply to unapproved products sold online.
Phase 2 trials were relatively small (hundreds of participants) and lasted 24-48 weeks; Phase 3 trials lasted 40-80 weeks, so long-term safety, durability of effect and effect after stopping treatment are not established.
Gastrointestinal adverse events were the most commonly reported events in every trial; heart-rate increases, hypotension, dysaesthesia, discontinuations due to adverse events and, in the osteoarthritis trials, more serious adverse events with retatrutide than placebo were also reported.
Reported efficacy figures depend on the analysis method (for example treatment-regimen versus efficacy or hybrid estimands) and differ between populations; results from adults with obesity do not transfer to other groups.
All published human trials identified were sponsored by Eli Lilly and enrolled adults only; no cardiovascular-outcome or kidney-outcome trial results were identified among the publications reviewed.
The liver, body-composition and osteoarthritis findings are substudy or subgroup results measured by imaging or symptom scores, not clinical outcomes such as liver histology or joint structure.
Preclinical findings come from rodent and hamster models and cannot be assumed to apply to people.
Research and regulatory status
Retatrutide is in Phase 3 development. ClinicalTrials.gov lists completed Phase 3 studies including TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367) and TRANSCEND-T2D-1 (NCT06354660), with further Phase 3 studies (for example in kidney disease, cardiovascular and kidney outcomes, comparisons with tirzepatide and semaglutide, and maintenance of weight reduction) listed as active. No approved indication was identified in the sources checked.
In vitro pharmacology, obese mouse study and a Phase 1 single-ascending-dose study
Participants / model
In vitro receptor assays; obese mice; Phase 1 participants (age not stated in the abstract)
Sample size
not stated in the abstract
Principal findings
In vitro, LY3437943 showed balanced glucagon-receptor and GLP-1-receptor activity with more GIP-receptor activity. In obese mice it decreased body weight and improved glycaemic control, with glucagon-receptor-mediated energy expenditure adding to the calorie-intake reduction driven by GIP- and GLP-1-receptor activity. In the Phase 1 study, safety and tolerability were described as similar to other incretins, and body-weight reduction persisted to day 43 after a single dose.
Limitations
The abstract does not give the size or age of the Phase 1 population, and the Phase 1 data are from a single dose. Mouse results do not establish the same mechanism in people.
Adults with a BMI of 30 or higher, or 27 to under 30 with at least one weight-related condition
Sample size
338 adults
Principal findings
At 48 weeks the least-squares mean percentage change in body weight ranged from -8.7% in the lowest retatrutide group to -24.2% in the highest, compared with -2.1% with placebo. Gastrointestinal adverse events were the most common, were dose-related and mostly mild to moderate, and heart rate increased in a dose-dependent manner, peaking at 24 weeks and declining thereafter.
Limitations
Phase 2 with a 48-week duration; sponsor-funded (Eli Lilly). Results describe adults with obesity or overweight and may not apply to other groups.
Randomised, double-blind, double-dummy, placebo- and dulaglutide-controlled Phase 2 trial
Participants / model
Adults aged 18-75 years with type 2 diabetes (HbA1c 7.0-10.5%, BMI 25-50 kg/m2) treated with diet and exercise alone or stable metformin
Sample size
281 adults randomised
Principal findings
At 24 weeks, HbA1c reductions with retatrutide were greater than placebo in all but the lowest-dose group, and greater than dulaglutide in two of the higher-dose groups. Body weight decreased dose-dependently by 36 weeks. Mild-to-moderate gastrointestinal events were more frequent with retatrutide, with no severe hypoglycaemia and no deaths reported.
Limitations
Phase 2, conducted at 42 US centres over 36 weeks of primary follow-up; population was mostly White and sponsor-funded.
Sanyal AJ, Kaplan LM, Frias JP, et al. · Nature medicine · 2024
Design
Randomised, double-blind, placebo-controlled Phase 2a substudy of the Phase 2 obesity trial
Participants / model
Participants from the Phase 2 obesity study who had MASLD and at least 10% liver fat
Sample size
98 participants
Principal findings
Mean relative change in liver fat at 24 weeks ranged from -42.9% to -82.4% across retatrutide groups versus +0.3% with placebo (all P<0.001). Normal liver fat (<5%) was reached by 27% to 86% of retatrutide participants and 0% of placebo participants. Liver-fat reductions were significantly related to changes in body weight, abdominal fat and metabolic measures.
Limitations
Small substudy with a liver-fat imaging endpoint at 24 weeks; no histology or clinical liver outcomes are reported in the abstract.
Adults with obesity without diabetes; subgroups with knee osteoarthritis and with obstructive sleep apnoea
Sample size
2,339 participants randomised
Principal findings
Mean percent change in body weight was -17.6%, -23.7% and -25.0% across the three retatrutide groups versus -3.9% with placebo (treatment-regimen estimand). In the knee osteoarthritis subgroup (574 participants) pain scores fell more than with placebo, and in the sleep apnoea subgroup (243 participants) the apnoea-hypopnoea index fell more than with placebo. The most common adverse events were gastrointestinal.
Limitations
Results apply to adults with obesity without diabetes over 80 weeks and depend on the estimand used; the abstract does not give detailed adverse-event rates.
Adults (18 years or older) with a BMI of 27 kg/m2 or higher and type 2 diabetes on stable treatment
Sample size
1,152 participants randomised
Principal findings
Mean percentage change in body weight at week 80 was -11.9%, -16.8% and -18.8% across the three retatrutide groups versus -5.1% with placebo. Gastrointestinal events, hypotension and dysaesthesia were reported more often with retatrutide, and permanent discontinuation due to adverse events or death was more frequent in the two higher-dose groups than with placebo. All deaths were judged by investigators to be unrelated to the study intervention.
Limitations
Sponsor-funded; discontinuation rates were higher in some retatrutide groups, and results apply to adults with obesity and type 2 diabetes over 80 weeks.
Adults (18 years or older) with type 2 diabetes inadequately controlled by diet and exercise alone (HbA1c 7.0-9.5%, BMI at least 23 kg/m2)
Sample size
537 participants randomised
Principal findings
HbA1c fell by 1.69% to 1.94% across retatrutide groups versus 0.81% with placebo, and body weight changed by -11.5% to -15.3% versus -2.6% with placebo. The most frequent adverse events were generally mild to moderate gastrointestinal events; discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo.
Limitations
40-week monotherapy trial in a population with a short mean diabetes duration (2.5 years); long-term and comparative outcomes are not addressed.
Briand F, Le Cudennec C, Grasset E, et al. · Obesity (Silver Spring, Md.) · 2026
Design
Preclinical efficacy study in diet-induced obese MASH models
Participants / model
Diet-induced obese MASH mouse and hamster models
Sample size
not stated in the abstract
Principal findings
In mice, retatrutide reduced body weight by 31% versus vehicle, along with insulin resistance index, hepatic steatosis score and lipids. In hamsters it reduced HOMA-IR, plasma triglycerides and LDL-cholesterol and halved hepatic triglyceride content, although histopathological scoring was not reduced.
Limitations
Rodent models; group sizes are not stated in the abstract and the hamster histology did not improve.
Preclinical combination study with pair-feeding and weight-matching experiments
Participants / model
Diet-induced obese male rats
Sample size
not stated in the abstract
Principal findings
Daily co-administration of retatrutide with cagrilintide was reported to reduce body weight and food intake more than the single agents and more than matched combinations including semaglutide or tirzepatide. Pair-feeding studies indicated that the enhanced weight loss could not be explained by reduced food intake alone.
Limitations
Male rats only and a combination not described as tested in humans in this report; findings may not translate to people.
Critical narrative review (evidence available through 11 September 2026)
Participants / model
Published and sponsor-disclosed retatrutide literature
Sample size
not applicable (narrative review)
Principal findings
The review describes retatrutide as an investigational once-weekly lipidated 39-residue peptide and discusses estimands, discontinuation and selection into trial extensions. It lists gastrointestinal adverse events, dysaesthesia, heart-rate changes and the functional consequences of lean-mass loss as requiring further evaluation, and states that comparative effectiveness, long-term outcomes and regulatory review remain essential.
Limitations
Narrative review rather than a systematic one, and written before several Phase 3 reports were peer-reviewed; some sponsor topline figures it cites were described as provisional.